New York State Psychiatric Institute: Opioid-Related Disorders trials

The registry lists 43 Opioid-Related Disorders studies with New York State Psychiatric Institute as lead sponsor. 2 are open to participants now and 26 have results posted.

Phase 1 8Phase 2 29Phase 3 12Phase 4 1No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use DisorderRecruitingNCT05011266Phase 2/3
• Clinical Trials of Multivalent Opioid Vaccine ComponentsRecruitingNCT04458545Phase 1/2
• Culturally Centering Medications for Opioid Use Disorder With American Indian and Alaska Native CommunitiesCompletedNCT04958798Not applicableResults posted
• Surmounting Withdrawal to Initiate Fast Treatment With NaltrexoneCompletedNCT04762537Not applicableResults posted
• Lofexidine for Management of Opioid Withdrawal With XR-NTX TreatmentCompletedNCT04056182Phase 2Results posted
• An Open-Label Pilot Study of Sublocade as Treatment for Opiate Use DisorderCompletedNCT03861338Phase 1/2Results posted
• Evaluation of Doxazosin to Alter the Abuse of OxycodoneTerminatedNCT03415581Phase 2Results posted
• A Study to Evaluate the Abuse Potential of Oxymorphone Compared to Other Mu Opioid Agonists.CompletedNCT03389750Phase 2Results posted
• A Strategy to Improve Success of Treatment Discontinuation in Buprenorphine RespondersCompletedNCT03232346Phase 3Results posted
• Medication Development for Opioid and Alcohol AbuseCompletedNCT03205423Phase 2Results posted
• Lorcaserin in Combination With XR-Naltrexone for Relapse Prevention in Opioid Use DisorderCompletedNCT03169816Phase 2/3Results posted
• Buprenorphine as Adjunct to Outpatient Induction Onto VivitrolTerminatedNCT03113409Phase 2/3Results posted
• Imaging the Effects of rTMS on Chronic PainTerminatedNCT02687360Not applicableResults posted
• Glutamatergic Modulation to Facilitate Naltrexone Initiation in Opioid DependenceCompletedNCT02437344Phase 2Results posted
• Buprenorphine/Naloxone Stabilization and Induction Onto Injection NaltrexoneCompletedNCT02294253Phase 2/3Results posted
• Prescription Opioid Abuse Among Pain Patients: Predictors of RelapseCompletedNCT01967641Phase 2Results posted
• Nalrexone Facilitated Discontinuation of BuprenorphineCompletedNCT01895036Phase 1/2Results posted
• Effects of Ibudilast on Oxycodone Self-administration in Opioid AbusersCompletedNCT01740414Phase 2Results posted
• Effects of Pioglitazone, a PPARgamma Receptor Agonist, on the Abuse Liability of OxycodoneCompletedNCT01395784Phase 2Results posted
• Dronabinol Naltrexone Treatment for Opioid DependenceCompletedNCT01024335Phase 2/3Results posted
• Phase IIa Study of AV411, a Glial Activation Inhibitor, for Opioid WithdrawalCompletedNCT00723177Phase 2Results posted
• Abuse Liability of Suboxone Versus SubutexCompletedNCT00710385Phase 3Results posted
• Buprenorphine Maintenance Treatment of Opioid Dependence in Primary Care: A Randomized Clinical TrialCompletedNCT00684554Phase 2/3Results posted
• Behavioral Naltrexone Therapy for Promoting Adherence to Oral Naltrexone vs Extended Release Injectable Depot NaltrexoneCompletedNCT00577408Phase 3Results posted
• Memantine as a Supplement to Naltrexone in Treating Heroin DependenceCompletedNCT00476242Phase 2/3Results posted
• Gabapentin Treatment of Benzodiazepine Abuse in Methadone Maintenance PatientsCompletedNCT00420771Phase 2Results posted
• Prescription Opioid Effects in Abusers Versus Non-AbusersCompletedNCT00158184Phase 2Results posted
• Memantine and Naltrexone Treatment for Opioid DependenceCompletedNCT00125515Phase 2Results posted
• Sublingual Dexmedetomidine for Treating Opioid WithdrawalActive, not recruitingNCT05712707Phase 1/2
• Sublingual Buprenorphine Through Telemedicine vs In-Person Care as UsualWithdrawnNCT05339256Phase 2
• Cognitive Functioning in Opioid Use DisorderTerminatedNCT05001789Not applicable
• A Study of SPG Block for Opioid WithdrawalCompletedNCT04946656Not applicable
• Anti-suicidal Effects of Buprenorphine in Opioid Use DisorderWithdrawnNCT04234516Phase 4
• Facilitating Rapid Naltrexone InitiationActive, not recruitingNCT03345173Phase 3
• NT-814: Evaluation of Its Ability to Alter the Abuse Liability of Oxycodone in an Exploratory Clinical StudyWithdrawnNCT02692157Phase 1/2
• Medication-Assisted Treatment for Youth With Substance Use DisordersCompletedNCT02593474Phase 1
• Improved Strategies for Outpatient Opioid DetoxificationCompletedNCT01377610Phase 1
• Study of Buprenorphine Maintenance Treatment for Opioid Dependence in Primary CareCompletedNCT00471042
• Behavioral Naltrexone Therapy: A Novel Treatment for Heroin DependenceCompletedNCT00332228Phase 2
• Opiate Dependence: Combined Naltrexone/Behavior Therapy - 1CompletedNCT00238914Phase 2
• HIV Counseling Intervention for Methadone-Maintained Patients - 2CompletedNCT00061100Phase 1
• Treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD) in Methadone Patients - 1CompletedNCT00061087Phase 2/3
• A Laboratory Model for Heroin Abuse Medications - 8CompletedNCT00000273Phase 2